HC Wainwright Reaffirms “Buy” Rating for MediWound (NASDAQ:MDWD)

MediWound (NASDAQ:MDWD)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $25.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 49.52% from the stock’s previous close.

MediWound Stock Up 4.4 %

Shares of MediWound stock opened at $16.72 on Friday. The company has a market cap of $180.34 million, a PE ratio of -5.77 and a beta of 0.80. MediWound has a 52 week low of $11.04 and a 52 week high of $24.00. The business has a 50 day moving average price of $17.24 and a 200-day moving average price of $17.64.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the previous year, the company earned ($0.24) earnings per share. As a group, research analysts anticipate that MediWound will post -2.6 EPS for the current year.

Institutional Trading of MediWound

Institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Management LLC purchased a new stake in shares of MediWound during the third quarter valued at approximately $89,000. Rhumbline Advisers bought a new position in MediWound during the second quarter valued at $131,000. Barclays PLC grew its holdings in MediWound by 311.3% during the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 8,449 shares during the period. Point72 Asset Management L.P. bought a new position in MediWound during the third quarter valued at $212,000. Finally, Bank of New York Mellon Corp bought a new position in MediWound during the second quarter valued at $342,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.